Posted by Michael Wonder on 07 Nov 2020
Ligand's partner Sedor Pharmaceuticals receives FDA approval for Sesquient for the treatment of status epilepticus in adult and paediatric patients
6 November 2020 - Captisol enabled product is stable at room temperature for timely administration at the point of patient care.
Ligand Pharmaceuticals today announced that its partner Sedor Pharmaceuticals has received approval from the U.S. FDA for Sesquient, a captisol enabled Fosphenytoin (fosphenytoin sodium for injection) for the treatment of status epilepticus in adult and paediatric patients.
